Vidhi Specialty Food Ingredients Limited logo

VIDHIING

NSE
Vidhi Specialty Food Ingredients Limited (SMALL CAP)
Commodities>Chemicals>Chemicals & Petrochemicals>Specialty Chemicals
287.15
1.65 (0.58%)
High VOLATILITY
As on 12 Jun 2026

Price History

Market Cap
₹1.43K Cr
SMALL CAP
P/E Ratio
29.2
Industry
Specialty Chemicals
52-Week Range
52W Low258.6+11.0%
52W High437.2-34.3%
Current Price
287.15
Circuit Limits (20%)
Lower Circuit229.72
Upper Circuit344.58
Reference Price
287.15

Investment Checklist

Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹348.5
Head and Shoulders on 1D (BREAKOUT CONFIRMED) — target ₹348.5
Trend: Price below most MAs — downtrend | Bearish MA stack (20<50<200)
Composite score -55.76 (STRONG_SELL) with 56.2% confidence
10/20 Bearish Cross detected 3 day(s) ago

Technical Analysis

Technical Analysis

Analysis from 2026-06-12

Confidence
56%

Trend

BEARISH
BEARISH

Price below most MAs — downtrend | Bearish MA stack (20<50<200)

EMA20
292.65
EMA50
297.44
EMA200
330.03

Price Action

MIXED
NEUTRAL
Higher Highs2
Higher Lows3
Lower Highs7
Lower Lows4

Support & Resistance Levels

Resistance (Above)
300.00
305.10
313.53
324.00
336.97
Support (Below)
281.15
272.05
259.13

Volume Analysis

TrendDECREASING
Change-71.00%
Unusual VolumeNo

Recent MA Crossovers

10/20 Bearish Cross
3 days ago
SELL

Stop Loss Levels

Fixed Risk

1% Risk284.28
3% Risk278.54
5% Risk272.79
7% Risk (Custom)
267.05

Technical Levels

1x ATR (Volatility)277.50
2x ATR (Swing)267.85
3x ATR (Trend)258.20
Immediate Support281.15

Financials

Financial Analysis

MetricMar '25Jun '25Sep '25Dec '25
Revenue₹100.9 Cr₹87.9 Cr₹75 Cr₹94.5 Cr
Net Profit₹11.9 Cr₹12.7 Cr₹10.6 Cr₹12.4 Cr
EPS₹2.54₹2.11₹2.49
Operating Profit₹20.8 Cr₹21 Cr₹18.4 Cr₹19.4 Cr
ROE
14.41%
ROCE
16.84%
Debt/Equity
0.22
Current Ratio
2.92
OPM
20.53%
NPM
13.15%

Peer Comparison

Specialty Chemicals

Peer Comparison

SymbolNamePriceChange
PIDILITINDPidilite Industries Limited₹1,535.50+2.45%
SRFSRF Limited₹2,743.00+3.18%
FLUOROCHEMGujarat Fluorochemicals Limited₹3,655.30-0.68%
NAVINFLUORNavin Fluorine International Limited₹7,303.00+2.04%
DEEPAKNTRDeepak Nitrite Limited₹1,669.90+3.57%
ATULAtul Limited₹6,517.50+0.32%
AARTIINDAarti Industries Limited₹440.60+2.98%
AETHERAether Industries Limited₹1,142.90+1.25%
BASFBASF India Limited₹3,356.50+3.21%
FINEORGFine Organic Industries Limited₹4,724.70+1.02%

Corporate Information

Large Deals

View All

Bulk, Block and Short deals reported for this stock.

Loading Deals...

Corporate Actions

Recent actions

View All
Ex DatePurposeType
14 Nov 2025
Interim Dividend - Re 1.50 Per Share
INTERIM_DIVIDEND
17 Sept 2025
Dividend - Rs 1.50 Per Share
DIVIDEND
01 Aug 2025
Interim Dividend - Rs 1.50 Per Share
INTERIM_DIVIDEND
24 Jan 2025
Interim Dividend - Rs 1.50 Per Share
INTERIM_DIVIDEND
19 Nov 2024
Interim Dividend - Re 1 Per Share
INTERIM_DIVIDEND

Announcements

Latest updates

View All
DateDescriptionLink
25 May 2026
Clarification - Financial Results
-
19 May 2026
Analysts/Institutional Investor Meet/Con. Call Updates
15 May 2026
Copy of Newspaper Publication
14 May 2026
Analysts/Institutional Investor Meet/Con. Call Updates
14 May 2026
Investor Presentation

Board Meetings

Upcoming and past meetings

View All
DatePurposeLinks
14 May 2026
Financial Results
14 May 2026
Board Meeting Intimation
02 Feb 2026
Board Meeting Intimation
02 Feb 2026
Financial Results/Dividend
10 Nov 2025
Financial Results/Dividend

Corporate Events

Upcoming results & meetings

View All

No upcoming events found

We couldn't find any scheduled corporate actions for this symbol at the moment.

Shareholding Pattern

Shareholding Pattern

As of Dec 2025

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for VIDHIING

View All
Venus Remedies gets Saudi FDA approval for speciality oncology therapy
positive
ET Markets - Industry 21d ago

Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

GLOBALSPECIALITYVENUSREMVIDHIINGChemicalsConsumer Services
NEWS
positive
Business Standard - Markets 22d ago

Venus Remedies receives Saudi FDA approval for Plerixafor

Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets.

RELIANCERELINFRAVALUEVENUSREMVIDHIINGChemicalsFinancial Services
NEWS
positive
Business Standard - Markets 30d ago

Vidhi Specialty Food Ingredients consolidated net profit rises 10.50% in the March 2026 quarter

Sales rise 12.01% to Rs 122.68 crore

VIDHIINGChemicals

Frequently Asked Questions